Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months (BALL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00628108
First received: February 22, 2008
Last updated: August 26, 2014
Last verified: December 2009

February 22, 2008
August 26, 2014
March 2008
September 2008   (final data collection date for primary outcome measure)
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR) [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in RR Interval [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
    The RR interval refers to the respective time interval in the Electrocardiogram (ECG)
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in PR Interval [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
    The PR interval refers to the respective time interval in the Electrocardiogram (ECG)
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QRS Duration [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
    The QRS duration refers to the respective time interval in the Electrocardiogram (ECG)
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT Interval [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
    The QT interval refers to the respective time in the Electrocardiogram (ECG)
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
    The QT interval refers to the respective time interval in the Electrocardiogram (ECG)
  • Absolute Value of QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) at Visit 3 (Day 7) [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    The QT interval refers to the respective time interval in the Electrocardiogram (ECG)
  • Absolute Value of QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    The QT interval refers to the respective time interval in the Electrocardiogram (ECG)
To evaluate the safety of levocetirizine in pediatric subjects aged from 6 months to 11 months. [ Time Frame: 2 weeks ]
Complete list of historical versions of study NCT00628108 on ClinicalTrials.gov Archive Site
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Total Bilirubin [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Alanine Aminotransferase (ALT) [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Aspartate Aminontransferase (AST) [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Blood Urea Nitrogen [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
  • Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Blood Creatinine [ Time Frame: Baseline, 14 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria.

To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Allergic Rhinitis
  • Chronic Urticaria
  • Drug: Levocetirizine 1.25 mg
    Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
    Other Name: Xyzal
  • Other: Placebo
    Placebo oral liquid once a day for two weeks
  • Placebo Comparator: Placebo
    Intervention: Other: Placebo
  • Experimental: Levocetirizine
    Intervention: Drug: Levocetirizine 1.25 mg
Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010 Jul;31(4):290-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
69
September 2008
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Outpatient, male or female pediatric subject, aged from 6 to 11 months (6 months - < 1 year) at the randomization visit.
  • The subject must present at least one symptom most commonly associated with allergic rhinitis or chronic idiopathic urticaria.
  • Candidate for antihistamine treatment or received antihistamine in the past for similar symptoms as those presenting.

Exclusion Criteria:

  • Any clinically significant medical condition or abnormality other than the primary diagnosis for which an antihistamine is indicated.
  • Be initiating or changing the dose of an immunotherapy regimen during the course of the study (visit 1 to Visit 4).
  • Any ECG parameters, including a QTcF interval > 443 msec measured by an ECG obtained at the Screening Visit, outside the normal reference ranges.
  • Any clinical laboratory tests performed at Screening Visit, other than those related with the allergic condition, outside the reference ranges. Subjects having values outside the accepted reference range can be included if in the Investigator's opinion, they are of no clinical significance.
  • Personal history of seizure, febrile seizure or sleep apnea.
  • Below the lower 5th or above 95th percentile for body weight and/or height based upon CDC Growth Charts for Body Weight and Length.
  • Allergy or intolerance to levocetirizine dihydrochloride or its excipients, or to any other piperazine derivatives, such as hydroxyzine, cetirizine, cyclizine, meclozine, buclizine.
  • Current or past intake (including exposure through breast milk) of the following medications within the specified wash-out period before the Randomization Visit (V2):

    • Systemic corticosteroids within the past 28 days.
    • Leukotriene-receptor antagonists (e.g. montelukast [Singulair] or zafirlukast [Accolate] within the past 7 days).
    • Mast-cell stabilizers (e.g. cromolyn or nedocromil) within the past 7 days
    • Other antihistamines or cough and cold preparations (with the exception of single ingredient guaifenesin products), or OTC sleep aid medications within the past 7 days.
    • Systemic antibiotics within the past 7 days.
    • Other concomitant medications that will interfere with the study, in the opinion of the investigator.
  • Previous participation in another clinical/pharmacological trial within the past month prior to V1.
  • Have already participated in this study or participated in this study at another site.
  • Children of any member of the study site staff.
  • Sibling with sleep apnea or sudden infant death syndrome (SIDS).
  • Exposure to other conditions known to be potential risk factors for SIDS, such as but not limited to (this should be determined on a case by case basis taking into account the subject's entire medical history and environmental living conditions):

    • Mothers who smoked or abused drugs during pregnancy.
    • Extremely young mothers (defined as age 19 or younger when pregnant).
    • Children currently exposed to a caregiver which is a heavy cigarette smoker (defined as smoking at least a pack of cigarettes per day).
    • Babies who sleep regularly on their face or are not put to sleep on their backs.
    • Premature birth gestational age ≤ 37 weeks) or low birth weight (below 10 percentile for gestational age).
Both
6 Months to 11 Months
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00628108
A00423, RPCE08K2403, 2007-003458-28
Not Provided
UCB Pharma
UCB Pharma
Not Provided
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
UCB Pharma
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP